Peramivir Market to Reach US$ 335.48 Million by 2034 at 10.56% CAGR

added blog Health

2026-10-26 12:36:36 - Translate -

Globally, peramivir is an intravenous neuraminidase inhibitor approved for influenza in the US (Rapivab), Japan and South Korea (Rapiacta), China (Xiaoruiping), and several other markets. Demand centers on hospitalized and severe cases where oral drugs are impractical. Sales are strongly seasonal and follow flu outbreaks. Pandemic stockpiling adds a steadier layer of demand. According to The...

0 Comments 0 Shares 9 Views 0 Reviews